--- title: "觸媒製藥公司投資者警報：Kahn Swick & Foti, LLC 正在調查擬議出售觸媒製藥公司（CPRX）的價格和流程是否充分" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/285824076.md" description: "Kahn Swick & Foti, LLC 正在調查 Catalyst Pharmaceuticals, Inc. (CPRX) 擬議出售給 Angelini Pharma S.p.A. 的事宜，股東將獲得每股 31.50 美元。該公司旨在評估這一價格和出售過程是否合理，或者是否低估了該公司的價值。認為交易低估了 Catalyst 的股東可以聯繫 KSF 獲取更多信息" datetime: "2026-05-10T00:34:13.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285824076.md) - [en](https://longbridge.com/en/news/285824076.md) - [zh-HK](https://longbridge.com/zh-HK/news/285824076.md) --- # 觸媒製藥公司投資者警報：Kahn Swick & Foti, LLC 正在調查擬議出售觸媒製藥公司（CPRX）的價格和流程是否充分 Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. Under the terms of the proposed transaction, shareholders of Catalyst will receive $31.50 in cash for each share of Catalyst that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-cprx/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner lewis.kahn@ksfcounsel.com 855-768-1857 1100 Poydras St., Suite 960 New Orleans, LA 70163 View source version on businesswire.com: https://www.businesswire.com/news/home/20260509833692/en/ ### 相關股票 - [CPRX.US](https://longbridge.com/zh-HK/quote/CPRX.US.md) ## 相關資訊與研究 - [觸媒製藥公司宣佈與 Hetero Labs Ltd.就 FIRDAPSE®（amifampridine）專利訴訟達成和解 | CPRX 股票新聞](https://longbridge.com/zh-HK/news/285497648.md) - [電能實業：出售 UKPN 不代表業務策略轉變，地緣政治不會對業務構成重大影響](https://longbridge.com/zh-HK/news/287060090.md) - [長建：出售英國電力業務會否派特別息由各成員公司決定，無急切性出售其他資產](https://longbridge.com/zh-HK/news/287059003.md) - [ASIA COMM HOLD:出售倫敦住宅公寓，涉 448.5 萬英鎊](https://longbridge.com/zh-HK/news/286546272.md) - [Halper Sadeh LLC 正調查 Dominion Energy 股東是否獲得公平對價](https://longbridge.com/zh-HK/news/286787626.md)